{"product_id":"anti-axl-extracellular-fitc-antibody-bha21301322","title":"Anti-AXL (extracellular)-FITC Antibody","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eAnti-AXL (extracellular)-FITC Antibody is an antibody targeting AXL Receptor Tyrosine Kinase, Tyrosine-Protein Kinase Receptor UFO, AXL Oncogene, Tyro7, UFO, ARK Polyclonal raised in Rabbit (Fluorescein isothiocyanate (FITC)). This antibody is commonly used in FC, LCI to detect, localize, or compare expression of the target across samples.\u003c\/p\u003e  \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e \u003cul\u003e   \u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e AXL Receptor Tyrosine Kinase, Tyrosine-Protein Kinase Receptor UFO, AXL Oncogene, Tyro7, UFO, ARK (also reported as AXL Receptor Tyrosine Kinase, Tyrosine-Protein Kinase Receptor UFO, AXL Oncogene, Tyro7, UFO, ARK).\u003c\/li\u003e   \u003cli\u003e\n\u003cstrong\u003eImmunogen\/epitope region:\u003c\/strong\u003e Extracellular, N-term..\u003c\/li\u003e   \u003cli\u003e\n\u003cstrong\u003eHomology note:\u003c\/strong\u003e Mouse, Rat – 14 out of 15 amino acids residues identical (informative for cross-species interpretation).\u003c\/li\u003e   \u003cli\u003e\n\u003cstrong\u003eSpecies reactivity (as provided):\u003c\/strong\u003e Human, Rat, Mouse.\u003c\/li\u003e   \u003cli\u003e\n\u003cstrong\u003eLot quality control (as provided):\u003c\/strong\u003e Western blot analysis (unlabeled antibody, #ATR-032), and direct flow cytometry (labeled antibody)..\u003c\/li\u003e   \u003cli\u003e\n\u003cstrong\u003ePeptide confirmation:\u003c\/strong\u003e Confirmed by amino acid analysis and mass spectrometry.\u003c\/li\u003e   \u003cli\u003e\n\u003cstrong\u003eBlocking peptide:\u003c\/strong\u003e Available for antigen preadsorption control where appropriate.\u003c\/li\u003e   \u003cli\u003e\n\u003cstrong\u003eConjugate\/format:\u003c\/strong\u003e Fluorescein isothiocyanate (FITC) (may affect detection channel and background).\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eThese attributes help researchers interpret whether signal reflects the intended target in a given assay and sample context.\u003c\/p\u003e  \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eAXL, also known as Tyrosine Kinase Receptor UFO and Tyro7, is a member of the receptor tyrosine kinase TAM family, that includes the receptors Tyro3, AXL and MERTK 1,2.The TAM family receptors are widely expressed in normal cells and tissues, such as monocytes, platelets, endothelial cells, brain and heart, where they regulate cell survival, non-inflammatory clearance of apoptotic cells by phagocytic cells, natural killer cell differentiation, platelet aggregation, and more 1,2.The TAM family receptors show structural similarities with other tyrosine kinase receptors, that is, an extracellular N-terminal domain containing two immunoglobulin-like and two fibronectin 3 domains, followed by a hydrophobic single pass transmembrane domain, and a cytoplasmic C-terminal tail containing a tyrosine kinase domain1,2.Axl and the other TAM receptors can be activated via their ligands, growth arrest specific 6 protein (Gas6) and Protein S (Pros1), which are members of the family of vitamin K-dependent proteins 3.Both AXL receptor and its high affinity ligand Gas6, are key regulators of immune cell activation, and have been shown to be expressed in cancer cells where they promote survival and invasion and contribute to resistance to various therapies 3,4,5. AXL expression is linked to increased risk of metastasis and poor survival in a variety of solid cancers including breast cancer, non-small cell lung carcinoma, ovarian cancer, and clear cell renal carcinoma 3,4. AXL activation in cancer cells and various stromal cells also results in tumor microenvironment deregulation, leading to modulation of angiogenesis, fibrosis, immune response and hypoxia 3,4.Based on these findings, AXL has been identified as a critical therapeutic target for solid cancers, and indeed several therapeutic modalities including small molecules and monoclonal antibodies, are currently being developed 2, 4.\u003c\/p\u003e  \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e   \u003cli\u003eComparing target expression across perturbations, genotypes, or treatment conditions.\u003c\/li\u003e   \u003cli\u003eInterpreting localization shifts alongside pathway or phenotypic readouts.\u003c\/li\u003e   \u003cli\u003eUsing orthogonal controls (KO\/KD, peptide competition, isotype concepts) to support conclusions.\u003c\/li\u003e \u003c\/ul\u003e  \u003ch2\u003eCommon research applications\u003c\/h2\u003e \u003cul\u003e   \u003cli\u003eFlow cytometry (direct\/indirect): quantify target-positive populations and shifts in expression across subsets.\u003c\/li\u003e   \u003cli\u003eLive cell imaging (LCI): support extracellular-epitope detection on non-permeabilized cells when appropriate.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eInterpretation typically benefits from comparing matched sample sets (e.g., treated vs control, WT vs KO\/KD) and using orthogonal readouts where feasible.\u003c\/p\u003e  \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e   \u003cli\u003eIsoforms and post-translational modifications can shift apparent molecular weight or epitope accessibility across samples.\u003c\/li\u003e   \u003cli\u003eCross-species signal may depend on epitope conservation; consult the provided homology note when selecting models.\u003c\/li\u003e   \u003cli\u003ePermeabilization, fixation, and antigen retrieval can change accessibility of intracellular vs extracellular epitopes.\u003c\/li\u003e   \u003cli\u003eConceptual control: antigen preadsorption (blocking peptide) can help assess signal dependence on the immunogen region.\u003c\/li\u003e   \u003cli\u003eProvided control suggestions: Negative control: RIC-001-F.\u003c\/li\u003e   \u003cli\u003eApplication notes: see product-specific dilution\/usage notes and control concepts provided in the dataset.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003e\u003cstrong\u003eApplication abbreviations:\u003c\/strong\u003e CBE- Cell-based ELISA, FC- Flow cytometry, ICC- Immunocytochemistry, IE- Indirect ELISA, IF- Immunofluorescence, IFC- Indirect flow cytometry, IHC- Immunohistochemistry, IP- Immunoprecipitation, LCI- Live cell imaging, N- Neutralization, WB- Western blot. \u003cstrong\u003eSpecies abbreviations:\u003c\/strong\u003e H- Human, M- Mouse, R- Rat.\u003c\/p\u003e \u003cp\u003e\u003cstrong\u003eRecommended controls:\u003c\/strong\u003e Blocking peptide: BLP-TR032; Negative control: RIC-001-F.\u003c\/p\u003e \u003c!-- Sources (internal): - Alomone Labs product page scientific background (as provided in this catalog row) - UniProt Knowledgebase (target-level reference) - NCBI Gene (target-level reference) - General antibody validation principles (KO\/KD, peptide competition, isotype control concepts) --\u003e","brand":"Alomone Labs","offers":[{"title":"50 mcl \/ 1","offer_id":53064862826861,"sku":"ATR-032-F-50MCL-1","price":797.0,"currency_code":"USD","in_stock":true},{"title":"50 mcl \/ 2","offer_id":53064984527213,"sku":"ATR-032-F-50MCL-2","price":1397.0,"currency_code":"USD","in_stock":true},{"title":"50 mcl \/ 5","offer_id":53064984559981,"sku":"ATR-032-F-50MCL-5","price":2743.0,"currency_code":"USD","in_stock":true},{"title":"50 mcl \/ 10","offer_id":53064984592749,"sku":"ATR-032-F-50MCL-10","price":3764.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/ATR-032-F_FC1_J774_2.5mic-1.png?v=1772461096","url":"https:\/\/www.ebiohippo.com\/products\/anti-axl-extracellular-fitc-antibody-bha21301322","provider":"BioHippo","version":"1.0","type":"link"}